Egetis Therapeutics

Board/Management Information • May 17, 2021

PRESS RELEASE

Egetis Therapeutics AB Stockholm, Sweden, May 17, 2021

CEO and senior executives in Egetis Therapeutics acquire shares

Stockholm, Sweden, May 17, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Nicklas Westerholm, CEO, Yilmaz Mahshid, incoming CFO, and Henrik Krook, Vice President Commercial Operations, have acquired shares in the company.

Nicklas Westerholm has bought 10,290 additional shares, Yilmaz Mahshid has bought 30,194 additional shares and Henrik Krook has bought 30,000 additional shares. Their respective total holdings now amount to 37,715, 156,000 and 73,955 shares in addition to warrants and employee stock options.

For further information, please contact:

Nicklas Westerholm, CEO, Egetis Therapeutics Tel. +46 (0)73 354 20 62 Email: nicklas.westerholm@egetis.com

The information was submitted for publication, through the agency of the contact person set out above, at 2021-05-17, 14.:00 CET.

About Egetis Therapeutics

Egetis Therapeutics is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate is developed as the first potential treatment for patients with MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A Phase IIb clinical trial has been completed with significant and clinically relevant effects. A pivotal Phase IIb/III early intervention study has been initiated with the first patient dosed in Dec 2020 and interim results are expected in 2022. Emcitate holds Orphan Drug Designation (ODD) in the US and EU and was granted Rare Pediatric Disease Designation by the US FDA in November 2020. The drug candidate Aladote is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote has been granted Orphan Drug Designation in the US and an application for ODD was submitted in Europe in Q1 2021. Results from the PledOx POLAR program in Dec 2020 showed that PledOx did not meet the efficacy endpoint. After discussion with our partner Solasia, Egetis Therapeutics has decided to park the development of PledOx following the POLAR results.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com